GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » enVVeno Medical Corp (NAS:NVNO) » Definitions » Cash-to-Debt

enVVeno Medical (enVVeno Medical) Cash-to-Debt : 32.61 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is enVVeno Medical Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. enVVeno Medical's cash to debt ratio for the quarter that ended in Mar. 2024 was 32.61.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, enVVeno Medical could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for enVVeno Medical's Cash-to-Debt or its related term are showing as below:

NVNO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02   Med: 18.23   Max: No Debt
Current: 32.61

During the past 9 years, enVVeno Medical's highest Cash to Debt Ratio was No Debt. The lowest was 0.02. And the median was 18.23.

NVNO's Cash-to-Debt is ranked better than
82.01% of 856 companies
in the Medical Devices & Instruments industry
Industry Median: 1.875 vs NVNO: 32.61

enVVeno Medical Cash-to-Debt Historical Data

The historical data trend for enVVeno Medical's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

enVVeno Medical Cash-to-Debt Chart

enVVeno Medical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only 1.53 10.60 27.28 22.75 33.10

enVVeno Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.90 19.09 17.38 33.10 32.61

Competitive Comparison of enVVeno Medical's Cash-to-Debt

For the Medical Devices subindustry, enVVeno Medical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


enVVeno Medical's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, enVVeno Medical's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where enVVeno Medical's Cash-to-Debt falls into.



enVVeno Medical Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

enVVeno Medical's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

enVVeno Medical's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


enVVeno Medical  (NAS:NVNO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


enVVeno Medical Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of enVVeno Medical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


enVVeno Medical (enVVeno Medical) Business Description

Traded in Other Exchanges
Address
70 Doppler, Irvine, CA, USA, 92618
enVVeno Medical Corp is a medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
Executives
Hamed Alavi officer: Chief Technology Officer ENVVENO MEDICAL CORPORATION, 70 DOPPLER, IRVINE CA 92618
Francis Duhay director HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Sanjay Shrivastava director HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert Andrew Berman director, officer: CEO C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Matthew Jenusaitis director 2 GOODYEAR, IRVINE CA 92618
Robert Gray director 70 DOPPLER, IRVINE CA 92618
Marc H. Glickman officer: See Remarks 70 DOPPLER, IRVINE CA 92618
Biodyne Holding, S.a. 10 percent owner 13 RUE DE LA GARE, MORGES V8 1110
Craig Glynn officer: Chief Financial Officer 70 DOPPLER, IRVINE CA 92618
Marcus W. Robins director C/O HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert A Rankin officer: Chief Financial Officer 9200 SUNSET BLVD., SUITE 425, WEST HOLLYWOOD CA 90069
Browston Trading Ltd 10 percent owner P.O. BOX 20533, NICOSIA G4 1660
Robert W. Doyle director 70 DOPPLER, IRVINE CA 92618
Robert A. Anderson director 70 DOPPLER, IRVINE CA 92618
Susan Montoya officer: See Remarks 70 DOPPLER, IRVINE CA 92618